OPKO Health (NASDAQ:OPK) Stock Rating Lowered by StockNews.com

OPKO Health (NASDAQ:OPK) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Several other equities research analysts have also weighed in on the company. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a report on Tuesday, September 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th.

OPKO Health Price Performance

OPK stock opened at $1.51 on Thursday. The company has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.48. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -7.95 and a beta of 1.62. OPKO Health has a 12-month low of $0.85 and a 12-month high of $1.76. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average price of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,612,405 shares in the company, valued at $342,812,096.10. This trade represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders have acquired 1,304,255 shares of company stock worth $2,024,605. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc boosted its position in shares of OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares during the period. FMR LLC boosted its holdings in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health in the 3rd quarter valued at $45,000. Algert Global LLC acquired a new position in shares of OPKO Health during the 2nd quarter worth about $44,000. Finally, Private Advisor Group LLC grew its holdings in shares of OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.